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2017.—Aortic stiffening is a major independent risk factor for car-
diovascular diseases, cognitive dysfunction, and other chronic disor-
ders of aging. Mitochondria-derived reactive oxygen species are a key
source of arterial oxidative stress, which may contribute to arterial
stiffening by promoting adverse structural changes—including colla-
gen overabundance and elastin degradation—and enhancing inflam-
mation, but the potential for mitochondria-targeted therapeutic strat-
egies to ameliorate aortic stiffening with primary aging is unknown.
We assessed aortic stiffness [pulse-wave velocity (aPWV)], ex vivo
aortic intrinsic mechanical properties [elastic modulus (EM) of col-
lagen and elastin regions], and aortic protein expression in young (~6
mo) and old (~27 mo) male C57BL/6 mice consuming normal
drinking water (YC and OC) or water containing mitochondria-
targeted antioxidant MitoQ (250 M; YMQ and OMQ) for 4 wk. Both
baseline and postintervention aPWV values were higher in OC vs. YC
(post: 482  21 vs. 420  5 cm/s, P  0.05). MitoQ had no effect in
young mice but decreased aPWV in old mice (OMQ, 426  20, P 
0.05 vs. OC). MitoQ did not affect age-associated increases in aortic
collagen-region EM, collagen expression, or proinflammatory cyto-
kine expression, but partially attenuated age-associated decreases in
elastin region EM and elastin expression. Our results demonstrate that
MitoQ reverses in vivo aortic stiffness in old mice and suggest that
mitochondria-targeted antioxidants may represent a novel, promising
therapeutic strategy for decreasing aortic stiffness with primary aging
and, possibly, age-related clinical disorders in humans. The destiff-
ening effects of MitoQ treatment may be at least partially mediated by
attenuation/reversal of age-related aortic elastin degradation.
NEW & NOTEWORTHY We show that 4 wk of treatment with the
mitochondria-specific antioxidant MitoQ in mice completely reverses
the age-associated elevation in aortic stiffness, assessed as aortic
pulse-wave velocity. The destiffening effects of MitoQ treatment may
be at least partially mediated by attenuation of age-related aortic
elastin degradation. Our results suggest that mitochondria-targeted
therapeutic strategies may hold promise for decreasing arterial stiff-
ening with aging in humans, possibly decreasing the risk of many
chronic age-related clinical disorders.
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INTRODUCTION
Advancing age is a primary risk factor for the development
of numerous chronic degenerative diseases, which are the
leading causes of morbidity and mortality in the United States
and other developed nations (20, 30, 41). A key event under-
lying the etiology of many chronic age-related disorders is
stiffening of the large elastic arteries, specifically, the aorta.
Elevated aortic stiffness increases the pulsatile shear and pres-
sure experienced by the heart, blood vessels, and other organs,
which can have numerous pathophysiological effects contrib-
uting to the development of disease (23, 32, 34, 35, 38, 62).
Indeed, aortic pulse-wave velocity (aPWV), the gold-standard
measure of arterial stiffness, is a strong independent risk factor
for incident cardiovascular events among older adults (34, 50),
and it also predicts the development of chronic kidney disease,
stroke, cognitive impairment, and Alzheimer disease (2, 7, 18,
21, 43, 53). Current demographic trends forecast a major
increase in the number of older adults in the coming decades,
which will be accompanied by attendant increases in disease
prevalence and health care costs (19, 22, 56). As such, a top
biomedical research priority is to identify strategies that pre-
vent or reverse aortic stiffening with advancing age, as this
may help prevent, reduce, or delay the development of multiple
common disorders of aging.
A key mechanism underlying the development of age-re-
lated arterial stiffening may be vascular mitochondrial oxida-
tive stress and associated excessive production of mitochon-
dria-derived reactive oxygen species (mtROS). Mitochondria
are now recognized as a primary source of arterial oxidative
stress with aging and cardiovascular diseases (1, 4, 5, 16, 31,
38, 55, 61), and evidence from genetic models indicates that
experimental modulation of mtROS affects large elastic artery
stiffening. For example, age-related arterial stiffening, patho-
logical remodeling, and vascular disease are accelerated in
mice deficient in the mitochondrial antioxidant protein manga-
nese superoxide dismutase (SOD2) (61). In support of a role
specifically for mitochondria-derived oxidative stress, selective
deletion of a cytosolic isoform of prooxidant enzyme NADPH
oxidase (NOX1/2)—with the mitochondrial isoform (NOX4)
intact—does not prevent age-related arterial stiffening in the
setting of atherosclerosis (55), implicating mtROS as a key
driver of age-related arterial pathology.
Excessive levels of arterial mtROS may promote arterial
stiffness via redox-related alterations in structural protein turn-
over and through induction of proinflammatory signaling.
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Changes in arterial wall structure are a major mechanism by
which the large elastic arteries stiffen with age (9, 17, 24, 32,
62); specific structural alterations include increased deposition
of the load-bearing protein collagen and degradation and frag-
mentation of elastin (17, 24, 42). Oxidative stress, including
that derived specifically from mitochondria, alters the activity
of the enzymes involved in structural protein turnover and
shifts the balance of synthesis and breakdown toward collagen
deposition and elastin degradation (9, 17, 24, 38, 55, 61, 62),
contributing to dysregulation of structural protein homeostasis
and consequent arterial stiffening.
Mitochondria-derived ROS are also emerging as important
for promoting and sustaining arterial inflammation, a hallmark
of arterial aging and critical mediator of arterial stiffening (24,
38, 39, 57). A proinflammatory environment in the vasculature,
secondary to excessive mtROS production, may contribute to
arterial stiffening through many mechanisms, including induc-
tion of gene expression patterns that alter structural protein
turnover, impairment of vascular endothelial function, in-
creases in vascular smooth muscle cell tone, and further inva-
sion of the vascular wall by proinflammatory mediators that
also reinforce oxidative stress (24, 31, 32, 39, 57, 61).
Our laboratory recently demonstrated that treating old mice
with the mitochondria-targeted antioxidant MitoQ to lower
mitochondrial oxidative stress completely reversed the age-
related impairment in arterial endothelial function in old mice
(15). However, the effects of mitochondria-targeted antioxi-
dants on aortic stiffness with primary aging have never been
investigated. Therefore, in this study, we tested the hypothesis
that 4 wk of MitoQ supplementation in the drinking water
would decrease aortic stiffness (as assessed in vivo by aPWV)
in old mice. To gain insight into the potential underlying
mechanisms, we also assessed the collagen- and elastin-medi-
ated contributions to intrinsic aortic stiffness (assessed ex vivo
in aortic rings), aortic protein expression of these key structural
proteins, and aortic expression of inflammatory cytokines.
METHODS
All studies were approved by the Institutional Animal Care and Use
Committee at the University of Colorado Boulder and conformed to
the Guide for the Care and Use of Laboratory Animals (National
Research Council, 2011).
Mice. Male C57BL/6 mice, an established model of age-related
vascular dysfunction (15, 48), were purchased from the aging colony
at the National Institute on Aging at ~4 or ~25 mo of age and allowed
to acclimate to our facilities for 2 wk before beginning treatment.
Mice were housed in standard cages on a 12:12-h light-dark cycle and
were allowed access to normal rodent chow (Harlan 7917) and water
ad libitum. Body mass and water intake were monitored regularly
throughout the study.
MitoQ treatment. On the basis of reports of effective dose and
duration of treatment with MitoQ and our previous work (15, 40, 46),
mice were randomly assigned to treatment with MitoQ [250 M; in
the form of Mitoquinone mesylate adsorbed to -cyclodextrin (~22%
MitoQ by weight) from Antipodean Pharmaceuticals, San Francisco,
CA]. Young MitoQ-treated (YMQ, ~6 mo., n  11) and old MitoQ-
treated (OMQ, ~27 mo, n  10) mice were compared with mice
provided normal drinking water [young control (YC, ~8 mo, n  8)
and old control (OC, ~27 mo, n  10)] for 4 wk, a duration we have
previously shown to be effective in reversing age-related arterial
endothelial dysfunction (15). MitoQ was prepared fresh (the prepara-
tion is water-soluble) and administered in light-protected water bottles
changed every 3 days.
In vivo assessment of arterial stiffness: aortic pulse-wave velocity.
In vivo arterial stiffness was assessed at baseline and after4 wk of
MitoQ treatment by aortic pulse-wave velocity (aPWV) using Dopp-
ler ultrasound, as previously described by our laboratory (11, 28).
Briefly, mice were anesthetized via inhaled isoflurane (1.5–2%) and
positioned supine on a warmed platform with paws secured to elec-
trocardiogram leads. Doppler probes were placed at the transverse
aortic arch and abdominal aorta to detect pulse waves. Three consec-
utive 2-s recordings were made for each animal and used to determine
time delay between the electrocardiogram R-wave and the foot of the
Doppler signal for each site (timeabdominal and timetransverse).
aPWV was then calculated as aPWV  (physical distance between
the two probes)/(timeabdominal  timetransverse) and reported in
centimeters per second.
To examine the potential role of changes in blood pressure to
treatment-related differences in aPWV, we assessed systolic and
diastolic blood pressure at baseline and after 4 wk of MitoQ or normal
drinking water consumption using the CODA noninvasive tail-cuff
system, as previously described (11, 28). The pressure measurements
from 20 collection cycles (following five acclimation cycles) on each
of three consecutive days were averaged for each mouse at each time
point.
Ex vivo assessment of arterial stiffness: intrinsic mechanical
stiffness. After all in vivo assessments were completed, mice were
euthanized and aortas were harvested for measurements of ex vivo
intrinsic mechanical stiffness and protein expression. Two 1-mm
aortic rings from the thoracic region (dissected free of surrounding
connective tissue) were used to assess intrinsic aortic stiffness via
wire myography, as described previously by our laboratory (6, 10, 14,
28). Aortic rings were loaded into heated myograph chambers (Danish
Myo Technology, Aarhus, Denmark) with calcium-free PBS. After
three cycles of prestretching were completed, ring diameter was
increased to achieve 1 mN force and then incrementally stretched by
~10% every 3 min until failure. The force corresponding to each
stretching interval was recorded and used to calculate stress and strain,
defined as follows: Strain (	)   d/d(i), where d is diameter, d(i) is
initial diameter; Stress (t)  	L/2HD, where L is one-dimensional
load, H is wall thickness determined by histology, and D is vessel
length.
The slope of the stress-strain curve was used to determine the
elastic modulus in the collagen-dominant and elastin-dominant re-
gions of the curve, as described below.
Collagen elastic modulus. When aortic rings are subjected to
stress-strain testing, the region of the stress-strain curve corresponding
to the highest forces represents the stretching of predominantly
collagen fibers (25, 47). The elastic modulus of the collagen-dominant
region was determined as the slope of the linear regression fit to the
final four points of the stress-strain curve, as described previously (6,
14, 28). See (Fig. 2) for representative stress-strain curve.
Elastin elastic modulus. During stress-strain testing in aortic rings,
the region of the stress-strain curve corresponding to the stretching of
exclusively elastin fibers is a lower-force region before collagen fiber
engagement that can be identified as the portion of the stress-strain
curve where curvature (determined from the second derivative of the
stress-strain curve) is approximately zero; the engagement of collagen
fibers is indicated by an elevation in the curvature (nonzero second
derivative) (25). To determine the boundaries of the elastin region of
our stress-strain curves, we calculated the roots of the second deriv-
ative of a 7th-order polynomial fit to the data (R2 
 0.99). The first
root was considered the boundary between the very low-force region
and the elastin region, and the second root was considered the
boundary between the elastin region and the onset of collagen fiber
engagement (25). The elastic modulus of the elastin region was then
determined as the slope of the linear regression fit to the stress-strain
data between the two points. See Fig. 2 for the representative stress-
strain curve.
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Aortic protein expression. Aortic expression of structural proteins
collagen-I and -elastin was determined in aortic homogenates by
standard Western blot techniques and immunohistochemistry (IHC) in
aortic sections, as previously described (6, 11, 28). Aortic protein
expression of inflammatory cytokines was determined using a custom
multiplex ELISA (Ciraplex, Aushon Biosystems, Billerica, MA), as
previously described (27, 29).
Before Western blot analysis and cytokine multiplex, aortas were
homogenized in radio-immunoprecipitation assay lysis buffer, and
protein concentration was determined using the Pierce BCA assay kit
(ThermoFisher Scientific, Fremont, CA).
For Western blot analysis, 15 g of aortic protein were loaded onto
4–12% polyacrylamide gels and then transferred onto nitrocellulose
membranes (Criterion System; Bio-Rad, Hercules, CA). Membranes
were incubated (overnight at 4°C) with primary antibodies: collagen-I
(1:1,000; Millipore, Burlington, MA), -elastin (1:200; Abcam, Cam-
bridge, MA), and glyceraldehyde 3-phosphate dehydrogenase (1:
1,000, normalizer, GAPDH; Cell Signaling, Danvers, MA). Proteins
were visualized on a digital acquisition system (ChemiDoc-It, UVP,
Upland, CA) using chemilluminescence with horseradish peroxidase-
conjugated secondary antibodies (Jackson ImmunoResearch, West
Grove, PA) and ECL substrate (Pierce, Rockford, IL). Relative
intensity was quantified using ImageJ software and normalized to
GAPDH intensity (obtained from the same blots after stripping) and
then expressed as a ratio of the mean intensity of the young control
group.
For cytokine multiplex, 15 g of aortic lysate were loaded into
microplate wells, and an assay was performed according to the
manufacturer’s instructions. The multiplex plates were custom de-
signed (custom Ciraplex, Aushon) for detection of the following
murine proinflammatory cytokines: IL-1, IL-6, IL-10, and IFN-.
Images were captured using Cirascan imager (Aushon), and results
were analyzed with Cirasoft software (Aushon). If levels of a given
cytokine were undetectable (e.g., fell below the limit of detection of
the assay), samples were excluded from the analysis.
For IHC, ~1-mm thoracic aortic segments were frozen in OCT
compound in liquid nitrogen-cooled isopentane before sectioning.
Aortic sections (7 m) were fixed in acetone, washed in Tris buffer,
and stained using the Dako EnVision System-HRP-DAB kit, as
performed previously in our laboratory (11). Sections were incubated
for 1 h at 4°C with primary antibodies for -elastin (1:50; Abcam) or
collagen-I (1:200; Millipore) and then incubated with the labeled
polymer secondary for 30 min. Slides were dehydrated and cover-
slipped after a 10-min or 1-min exposure to diaminobenzidine (elastin
and collagen, respectively).
Stained aortic sections were imaged using a Nikon Eclipse TS100
photomicroscope under identical conditions. Quantification of the
integrated density of the stain was performed using ImageJ software
by a single investigator blinded to the group assignment of each
sample. Collagen-I expression was assessed in the whole artery
sections, comprising both the medial and adventitial layers, whereas
elastin expression was assessed in the medial layer, the primary site of
age-related changes in elastin expression (9, 10). Integrated density
values from four sections were averaged to provide a single value for
each protein per aorta, which are expressed relative to the mean of the
young control group.
Statistical analysis. All statistical analyses were performed using
SPSS 23.0 software (Armonk, NY). Data were first assessed for
outliers and normality/homogeneity of variance. Between-group dif-
ferences in morphological characteristics and aortic protein expres-
sion (Western blot, immunohistochemistry, and multiplex ELISA)
were determined using one-way ANOVA. Between-group differences
in elastic modulus (collagen and elastin regions) were determined
using a linear mixed model with age (young vs. old) and treatment
(control vs. MitoQ) as factors, whereas within-group differences in
aPWV and blood pressure were examined using a linear mixed model
that also included a repeated factor (preintervention vs. postinterven-
tion period). When a significant main effect was observed, Fisher’s
least significant difference post hoc tests were performed to determine
specific pair-wise differences.
RESULTS
MitoQ consumption across the 4-wk treatment period was
similar to our previous report and not different between young
and old mice (~1 mmol/day; Ref. 15). Select morphological
Fig. 1. MitoQ treatment reverses age-related aortic stiffness in mice. Aortic
pulse-wave velocity (aPWV) was assessed in young and old mice before
(baseline) and after (post) consumption of normal drinking water (YC and OC)
or MitoQ treatment (YMQ and OMQ) for 4 wk. n  8–11/group; error bars
represent means  SE *P  0.05 vs. YC and YMQ; **P  0.05 vs. OC and
OMQ baseline.
Table 1. General morphological characteristics and blood pressure
YC OC YMQ OMQ
Body mass, g 25.1  1.2 29.4  2.7* 26.0  1.4 28.5  3.0*
Heart mass, mg 128  11 175  22* 124  9 164  20*
Liver mass, g 1.34  0.06 1.41  0.16 1.34  0.18 1.37  0.38
Quadriceps mass, mg 163  28 138  27* 175  29 143  27*
Visceral fat mass, mg 306  70 302  89 256  71 229  118
Aorta diameter, m 749  72 780  47 789  77 785  43
Systolic BP, mmHg Pre: 105.1  10.1 Pre: 101.3  11.7 Pre: 101.2  6.7 Pre: 93.5  10.8
Post: 101.4  12.9 Post: 94.9  5.0 Post: 98.2  10.8 Post: 101.0  4.4
Diastolic BP, mmHg Pre: 73.3  11.5 Pre: 72.8  11.0 Pre: 73.1  4.7 Pre: 66.3  4.2
Post: 71.9  11.3 Post: 67.0  4.6 Post: 74.1  9.3 Post: 71.9  10.1
Data are presented as means  SD. YC, young control mice; OC, old control mice; YMQ, young MitoQ-treated mice; OMQ, old MitoQ-treated mice; BP,
blood pressure; Pre, baseline assessment (before treatment period); Post, assessment following 4-wk treatment period with MitoQ or normal drinking water. *P
0.05 vs. YC and YMQ.
1196 MITOCHONDRIAL ANTIOXIDANT REVERSES AORTIC STIFFNESS
J Appl Physiol • doi:10.1152/japplphysiol.00670.2017 • www.jappl.org
Downloaded from www.physiology.org/journal/jappl by ${individualUser.givenNames} ${individualUser.surname} (131.111.184.102) on June 18, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
characteristics and blood pressure are shown in Table 1.
Consistent with our previous study (15), 4 wk of MitoQ
treatment did not influence overall morphology; although there
were age-associated differences in body mass, heart mass, and
quadriceps mass, these were not different between mice receiv-
ing MitoQ vs. normal drinking water. There were no age- or
treatment-related differences in aortic diameter or systolic and
diastolic blood pressure.
MitoQ treatment reverses aortic stiffening in old mice. At
baseline, aPWV was significantly higher in old compared with
young mice, and aPWV was not significantly different from
baseline to postintervention in either young or old control mice
receiving normal drinking water (Fig. 1). In contrast, 4 wk of
MitoQ treatment significantly decreased aPWV in old mice to
levels similar to young mice following the intervention period.
MitoQ treatment had no effect on aPWV in young mice. These
results indicate that 4 wk of MitoQ treatment specifically
reverses aortic stiffening in old mice.
Potential mechanisms underlying the destiffening effects of
MitoQ treatment in old mice. In our previous study using
MitoQ treatment in old mice (15), the same dose and duration
of treatment as used in the present study normalized the
age-related elevation in aortic whole cell and mitochondria-
specific superoxide production, indicating a profound antioxi-
dant effect of MitoQ in arteries. To investigate further how
decreased levels of mtROS in aging arteries may contribute to
the destiffening effects of MitoQ, in the present study, we
investigated key mechanisms that have been implicated down-
stream of mitochondrial oxidative stress in the development of
age-related arterial stiffening, namely, changes in arterial struc-
tural proteins and inflammation.
Ex vivo aortic stiffness—collagen- and elastin-mediated
mechanical properties of aortic rings. The elastic modulus of
the collagen region of stress-strain curves was significantly
greater in old control vs. young control mice (Fig. 3A), whereas
the elastic modulus of the elastin region was significantly lower
in old control compared with young control mice (Fig. 3B),
indicating an age-related increase in intrinsic arterial stiffness
mediated by increased collagen and reduced elastin. MitoQ
treatment had no effect on the collagen elastic modulus, such
that the values in old and young MitoQ-treated mice were not
significantly different from old and young control mice, re-
spectively. However, in arteries from old mice treated with
MitoQ, the elastic modulus in the elastin region was signifi-
cantly greater than that of old control mice but remained
significantly lower than the elastin elastic modulus of young
MitoQ-treated mice, indicating attenuation of the age-related
decline in elastin.
Aortic expression of structural proteins. Consistent with our
intrinsic mechanical stiffness observations, aortic collagen pro-
tein expression was significantly greater (Fig. 4, A and B), and
aortic elastin expression was lower (Fig. 4, C and D, P 0.074
and 0.086, respectively) in old control versus young control
mice. MitoQ treatment did not affect aortic collagen content,
such that collagen expression in old MitoQ-treated mice was
not significantly different than that of old control mice,
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Fig. 2. Representative stress-strain curve for determination of ex vivo intrinsic
mechanical stiffness of aortic rings. Aortic rings were incrementally stretched
until tissue failure, as described in MATERIALS AND METHODS, and the tension
(stress, kPa) corresponding to each stretch was plotted against strain (change
in length relative to resting length) to generate a stress-strain curve. The elastic
modulus of the region of the curve corresponding to collagen fiber stretching
was determined as the slope of the line fit to the final four points on the curve
before tissue failure (collagen region elastic modulus). The region of the curve
corresponding to elastin fiber stretching was considered to lie between the very
low-force region and the onset of collagen fiber engagement, which were
identified as the first and second roots, respectively, of a seventh-order
polynomial fit to the stress-strain curve (25). The elastic modulus of the elastin
region of the curve was determined as the slope of the line fit between these
boundaries (elastin region elastic modulus).
Fig. 3. MitoQ treatment attenuates the age-related decline in elastin-mediated intrinsic mechanical properties but has no effect on collagen-mediated intrinsic
mechanical stiffness. A: collagen region elastic modulus of aortic segments from young and old control (YC and OC) and young and old MitoQ-treated (YMQ
and OMQ) mice. B: elastin region elastic modulus of aortic segments from YC, OC, YMQ, and OMQ mice. n  8–11/group; error bars represent means  SE.
*P  0.05 vs. YC and YMQ. #P  0.05 vs. OC and YMQ.
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whether assessed in whole artery homogenate by Western blot
analysis or in aortic sections via IHC. When measured in whole
artery homogenate by Western blot analysis, aortic elastin
levels in old MitoQ-treated mice were intermediate between
(and not significantly different from) those of either young
control or old control mice. However, when assessed via IHC
in the medial layer of aortas—the primary site of age-related
elastin degradation (9, 10)—elastin content in old MitoQ-
treated mice was greater than that of old control mice (P 
0.07).
Together with our observations of intrinsic mechanical prop-
erties, these results suggest that the reduction in in vivo aortic
stiffening in old mice after MitoQ treatment was mediated not
by effects on aortic collagen, but possibly by partial preserva-
tion of elastin.
Aortic inflammatory cytokine expression. Aortic expression
of proinflammatory cytokines IL-6, IL-10, and IFN- (Fig. 5,
A–C) was significantly higher, and expression of IL-1 (Fig.
5D) tended to be higher, in old compared with young control
mice, consistent with previous investigations demonstrating
elevated levels of arterial cytokines with aging and association
with vascular dysfunction (3, 27, 29, 44). Cytokine levels were
not affected by 4 wk of MitoQ treatment (P 
 0.05 OMQ vs.
OC for all cytokines), suggesting that the destiffening effects
of MitoQ were not mediated by changes in these aortic cyto-
kines. However, these results do not preclude the possibility
that MitoQ treatment may have influenced other components of
inflammatory signaling pathways.
DISCUSSION
The primary, novel finding of this study is that 4 wk of
treatment with the mitochondria-targeted antioxidant MitoQ in
old mice completely reverses the age-associated increase in
aortic stiffness, assessed in vivo as aPWV. Our observation
that MitoQ treatment decreases aortic stiffness in old mice
extends previous work with general antioxidant compounds
and adds to the evidence from transgenic and disease models
Fig. 4. MitoQ treatment attenuates the age-related reduction in aortic elastin expression but has no effect on aortic collagen expression. A: aortic collagen-I
expression assessed by Western blot analysis in aortic homogenates from young and old control (YC and OC) and young and old MitoQ-treated (YMQ and OMQ)
mice. Expression levels are presented normalized to GAPDH expression and relative to the mean of the YC group (error bars represent means  SE).
Representative images, comprising four continuous lanes, are presented below mean data. The collagen-I and GAPDH images represent the same segment of
the same blot. Any adjustments to the images were limited to changes in brightness and contrast made using ImageJ to optimize visualization, performed
uniformly on the entire image. n  6/group. *P  0.05 vs. YC. B: aortic collagen-I expression assessed by immunohistochemistry in whole aortic sections from
YC, OC, YMQ, and OMQ mice. Expression levels are presented relative to the mean of the YC group (error bars represent means  SE). Representative images
(whole sections and enlargements of the same sections) are presented to the right of the mean data. n 7–11/group. *P 0.05 vs. YC. C: aortic elastin expression
assessed by Western blot analysis in aortic homogenates from young and old control (YC and OC) and young and old MitoQ-treated (YMQ and OMQ) mice.
Expression levels are presented normalized to GAPDH expression and relative to the mean of the YC group (error bars represent means  SE). Representative
images, comprising four continuous lanes, are presented below mean data. The elastin and GAPDH images represent the same segment of the same blot. Any
adjustments to the images were limited to changes in brightness and contrast made using ImageJ to optimize visualization, performed uniformly on the entire
image. n  6/group. ^P  0.074 vs. YC. D: aortic elastin expression assessed by immunohistochemistry in the medial layer of aortic sections from YC, OC,
YMQ, and OMQ mice. Expression levels are presented relative to the mean of the YC group (error bars represent means  SE). Representative images (whole
sections and enlargements of the same sections) are presented to the right of the mean data. n  8–11/group. ^P  0.086 vs. YC; ^^P  0.075 vs. OC.
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that specifically implicate mitochondrial oxidative stress as a
key contributor to aortic stiffening. A previous preclinical
intervention study from our laboratory using the general anti-
oxidant compound TEMPOL established oxidative stress as a
key mechanism underlying age-related aortic stiffening (12),
and other strategies that decrease arterial oxidative stress also
ameliorate arterial stiffness (11, 13, 14, 28, 49). Recent work
with genetic and disease models indicates that mitochondria
are a major source of the vascular oxidative stress contributing
to arterial stiffness. Mice with genetic deletion of mitochon-
drial antioxidant enzyme SOD2, a model of excess mitochon-
drial oxidative stress, demonstrate exacerbation of age-related
aortic stiffening (61), and progression of age-related arterial
stiffening is unaffected in mice with genetic deletion of cyto-
solic prooxidant NADPH oxidase (NOX1/2) but intact mito-
chondria-localized NADPH oxidase (NOX4) (55). Our finding
here that in vivo treatment with the mitochondria-targeted
antioxidant MitoQ in old mice decreases aortic stiffness pro-
vides further support for mitochondrial oxidative stress as a
key mediator of arterial dysfunction with primary aging. Most
importantly, our results extend previous observations from
genetic and disease models (55) by demonstrating that a
pharmacological intervention targeting excessive mtROS pro-
duction reverses aortic stiffening in the setting of primary
aging in mice, thus establishing an essential platform for
translation to humans.
To gain initial mechanistic insight into the destiffening
effects of MitoQ treatment, we assessed intrinsic mechanical
stiffness ex vivo in aortic rings and examined both the colla-
gen- and elastin-predominant regions of the stress-strain
curves. In contrast to previous studies showing that the des-
tiffening effects of late-life interventions, including those as-
sociated with decreased whole cell and mitochondrial oxidative
stress, are primarily mediated by decreases in arterial collagen
content (9, 11, 12, 14, 37, 55), we observed that MitoQ
treatment had no significant effect on the collagen region
elastic modulus or aortic collagen expression but instead at-
tenuated the age-related decline in aortic elastin region elastic
modulus and tended to preserve elastin expression. Our finding
of partial elastin preservation with MitoQ treatment is consis-
tent with the observations that heterozygous SOD2-deficient
mice, a model of excess mtROS, show marked exacerbation of
age-associated declines in arterial elastin content (61) and that
lifelong caloric restriction, a setting of lower mtROS (26),
preserves arterial elastin content with aging (8). Collectively,
our results suggest that decreasing mitochondrial oxidative
stress may at least partially preserve elastin content in the
aorta, contributing to lower levels of stiffness.
Future studies are warranted to elucidate the mechanisms by
which decreased mitochondrial oxidative stress (via MitoQ
treatment) may preserve aortic elastin content in aging. One
possible link may be mtROS-mediated regulation of enzy-
Fig. 5. MitoQ treatment does not affect the age-related increase in aortic inflammatory cytokines. Expression of inflammatory cytokines IL-6 (n  7–10/group)
(A), IL-10 (n  7–9/group) (B), IFN- (n  7–10/group) (C), and IL-1 (n  4–10/group) (D) in aortic homogenates from young and old control (YC and OC)
and young and old MitoQ-treated (YMQ and OMQ) mice. Sample sizes reflect all aortic homogenates for which cytokine levels were detectable; samples were
excluded when cytokine levels were undetectable/below the limit of quantification of the assay. Error bars represent means  SE. *P  0.05 vs. YC. ^0.10 

P 
 0.05 vs. YC (P  0.08, OC vs. YC; P  0.06, OMQ vs. YC).
1199MITOCHONDRIAL ANTIOXIDANT REVERSES AORTIC STIFFNESS
J Appl Physiol • doi:10.1152/japplphysiol.00670.2017 • www.jappl.org
Downloaded from www.physiology.org/journal/jappl by ${individualUser.givenNames} ${individualUser.surname} (131.111.184.102) on June 18, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
mes that govern elastin turnover, including matrix metallopro-
teinases (MMP; Refs. 36 and 62)—changes in the activity of
which are associated with arterial stiffening in both mouse
models and human aging (32, 33, 58). For example, increased
levels of MMP-2, a key enzyme involved in elastin degradation
(9, 17, 59), accompany the loss of arterial elastin in heterozy-
gous SOD2 knockout mice (61). Further, primary aging in
preclinical models is associated with increased arterial MMP-2
expression (9, 59), and elevated aortic MMP-2 levels are also
observed in human aging (33). Collectively, these previous
studies suggest that age-related increases in mtROS may con-
tribute to arterial elastin degradation via increased MMP-2
activity and that targeting excess mtROS, e.g., via MitoQ
treatment, may attenuate elastin degradation, preserving
elastin content in large elastic arteries and contributing to
lower levels of stiffness. Although our results do not support
a role for MitoQ in decreasing total arterial collagen con-
tent, future studies could examine not only arterial content
of this key structural protein, but also changes in collagen
fiber orientation (17) and formation of cross-links among
proteins, both of which have the potential to influence
arterial stiffness (9, 23, 62).
It is also important to consider mechanisms other than
preservation of aortic elastin content that may have contributed
to the dramatic decrease in aortic stiffness we observed with
MitoQ treatment in old mice. In addition to structural changes,
age-related arterial stiffening is also mediated by hemody-
namic factors (including age-related reductions in vascular
endothelial function) and increased vasomotor tone (17, 24,
62). Although our data indicate that changes in resting blood
pressure did not contribute to the effects of MitoQ treatment, it
is plausible that some of the destiffening that we observed in
old mice was due to improvements in vascular endothelial
function. Our previous study (15) demonstrated that MitoQ
treatment increases endothelium-dependent dilation and nitric
oxide bioavailability in old mice, both of which are important
direct (e.g., effects on pulse pressure and smooth muscle tone)
and indirect (e.g., nitric oxide, regulation of structural protein
turnover) mediators of large elastic artery stiffness in vivo (17,
32, 38, 60, 62).
Aortic inflammatory cytokine levels were significantly ele-
vated in aortic tissue of old vs. young mice, consistent with
previous studies (27, 29, 44). Chronic low-grade arterial in-
flammation with aging, primarily mediated by NF-B activa-
tion, can be triggered by excessive oxidative stress—including
that derived from mitochondria—in a reciprocally reinforcing
process that serves to impair arterial function (3, 29, 54).
Although there is some evidence for a role of mtROS in
mediating arterial inflammation and consequent dysfunction in
atherosclerosis/disease models (31, 55), our observations in the
present study do not support an anti-inflammatory role for
MitoQ in reversing arterial stiffening in primary aging. After 4
wk of MitoQ treatment, there was no difference between old
control and old MitoQ-treated aortic cytokine levels, despite
the pronounced reversal of arterial stiffening in the latter. This
suggests that the destiffening effects of MitoQ were mediated
by a mechanism other than normalization of the aortic cyto-
kines that we assessed here. However, it remains possible that
MitoQ treatment influenced other components of inflammatory
signaling, and future studies are warranted to investigate these
possibilities.
Although the present study investigated the therapeutic ef-
ficacy of MitoQ in the setting of existing age-related aortic
stiffness, it would also be of clinical relevance to determine
whether targeting/decreasing mtROS earlier in life before the
onset of aortic stiffening could prevent or slow the progression
of pathological aortic remodeling and consequent cardiovascu-
lar sequelae. Given that excess mtROS are implicated as a key
factor in the pathogenesis of numerous age-related conditions,
including vascular dysfunction (1, 4, 5), it is possible that
limiting an age-related increase in mtROS via treatment in
early or midlife could prevent aortic stiffening. This possibility
is supported by work from disease and senescence models,
indicating that mitochondria-targeted therapeutics initiated be-
fore or at the onset of experimental insult or injury can prevent
development or slow progression of dysfunction (45, 51, 52).
Because low, physiological levels of mtROS are critical for the
maintenance of cellular homeostasis, any optimal long-term
therapeutic strategy would likely need to maintain mtROS at
physiological levels rather than eliminate them completely.
Conclusion. In conclusion, the present study demonstrates
that late-life treatment with a mitochondria-targeted antioxi-
dant, MitoQ, effectively reverses aortic stiffening in the setting
of primary aging. Our results suggest that this effect is medi-
ated at least partially by attenuation/reversal of the age-related
reduction in aortic elastin content, but additional work is
needed to conclusively determine the mechanism(s) underlying
the destiffening effect of MitoQ. Importantly, these results
indicate that mitochondria-targeted antioxidants may represent
a novel, promising therapeutic strategy for decreasing aortic
stiffness, and potentially decreasing the risk of multiple
chronic age-associated conditions in humans.
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